Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
A multicenter RCT demonstrates that drug-coated balloon (DCB) angioplasty significantly reduces 6-month restenosis and 1-year recurrent ischemic events compared to bare-metal stenting in patients with high-grade symptomatic intracranial ath
The multicenter TASTE-2 trial reveals that edaravone dexborneol significantly increases the likelihood of functional independence at 90 days for acute ischaemic stroke patients undergoing thrombectomy, particularly those presenting with a c
A sub-analysis of the FINGER trial reveals that individuals with specific grey matter patterns and lower vascular risk derive the most structural brain benefit from multimodal lifestyle interventions, highlighting the potential for personal
The ANGEL-REBOOT trial reveals that while bailout angioplasty (BAOS) increases short-term procedural risks, it significantly improves one-year functional outcomes and reduces stroke recurrence in patients with failed thrombectomy or high-gr
The landmark BHF PROTECT-TAVI trial reveals that cerebral embolic protection (CEP) does not reduce periprocedural stroke or cognitive impairment following TAVI. This large-scale study challenges the routine use of embolic filters, suggestin
A multicenter randomized trial confirms that a novel biodegradable PFO closure device is noninferior to nitinol devices, achieving high closure rates and disappearing from echocardiography within two years, potentially reducing long-term fo
A long-term analysis of the FOURIER trials reveals that achieving ultra-low LDL-C levels (<40 mg/dL) significantly reduces recurrent stroke and major cardiovascular events in stroke survivors, without increasing hemorrhagic stroke risk,
While the primary i-DEF trial results suggested futility for deferoxamine in unselected intracerebral hemorrhage patients, recent post hoc analyses reveal significant benefits in early neurological improvement, long-term recovery trajectori
A post hoc analysis of the SWITCH trial demonstrates that the clinical benefits of decompressive craniectomy in reducing death and severe disability are consistent across different anatomical locations of deep supratentorial intracerebral h
The C-GUARDIANS trial reveals that the CGuard MicroNet-covered stent significantly reduces embolic risks in high-risk carotid artery stenting, achieving a remarkably low 30-day DSMI rate of 0.95% and sustained neuroprotection through one ye
The RESOLVE trial demonstrates that graded sensorimotor retraining provides modest pain relief for chronic low back pain. A secondary analysis reveals that these benefits are consistent across most patient subgroups, suggesting that the int
A pivotal Phase 3 study published in NEJM demonstrates that Fremanezumab significantly reduces monthly migraine days in children and adolescents, offering a targeted, evidence-based preventive option for a population with high unmet medical
Highlights Background Dementia and depression are intertwined public health crises, together accounting for a substantial…
A large-scale study of 144,969 Medicare beneficiaries reveals that initial anticoagulant prescriptions for atrial fibrillation may not reduce ischemic stroke risk in patients over 66, while significantly increasing major bleeding hazards, s
A population-based study reveals that nearly one-quarter of TIA patients experience depression, which significantly increases the risk of mortality and disability, regardless of whether acute ischemic lesions are present on imaging.
A secondary analysis of the READAPT study reveals that patients with active cancer or hematological malignancies face significantly higher risks of recurrent stroke and bleeding while on dual antiplatelet therapy (DAPT) compared to those in
A large-scale cohort study demonstrates that the efficacy of dual antiplatelet therapy for minor stroke and TIA is highly time-dependent, with maximal benefits seen within 24 hours and a loss of therapeutic effect after approximately 42 hou
A comprehensive multi-cohort proteomic study identifies Oligodendrocyte Myelin Glycoprotein (OMG) as a causal biomarker for neurodegenerative resiliency, linking its peripheral abundance to axonal integrity and reduced risk of dementia and
A large-scale retrospective cohort study reveals that GLP-1 receptor agonists reduce the risk of subarachnoid hemorrhage by 34% and all-cause mortality by 37% in patients with type 2 diabetes and intracranial aneurysms, suggesting a potent
A multicenter cohort study (ERNA-IAO) demonstrates that endovascular recanalization significantly increases the risk of stroke and death compared to medical treatment alone in patients with symptomatic nonacute intracranial artery occlusion
Open language-specific specialty feeds and department pages.